Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
...stent (SES), which releases the therapeutic agent sirolimus over time to prevent restenosis, fared at least as well as those treated with vascular brachytherapy (VB). Moreover, the patients who received the drug eluting stent had fewer cardiac events afterwards. "The efficacy of the SES in native co...Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
...nce their FDA approval in 2003, stents coated with sirolimus (a pharmaceutical agent that prevents excess tissue growth) have been shown to greatly reduce restenosis. But some people suffer from rare, allergic-type reactions to the sirolimus-eluting stents (SES). According to research presented by Emory scie...Loyola study shows drug-coated stent induces less inflammation than bare metal stent
...S - In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill. "Inflammatory response is a sign of adva...New data supports CellCept's position as a world leader in solid organ transplantation
...e (modified USP), MMF and steroids vs. tacrolimus, sirolimus and steroids in de novo cardiac transplant recipie...e immunosuppression with mycophenolate mofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow-up. A...Tacrolimus + mycophenolate mofetil & steroids: Safe, effective in preventing acute cardiac rejection
...mulsion (CYA) + MMF and steroids, vs. tacrolimus + sirolimus (SRL) and steroids. "Though significant imp...fractory rejection, discontinued tacrolimus and/or sirolimus for renal dysfunction, and discontinued mycophenolate mofetil for leucopenia. There were also signif...Insights from intravascular ultrasound explore treatment benefits
...favor of everolimus as a preventative strategy and sirolimus in the regression of cardiac allograft vasculopathy."...Heart transplant survival: Results may be key to rejection prevention, detection, treatment
...ransplant disease (graft vasculopathy) with use of sirolimus from time of heart transplantation Results from a two-year study (Abstract #193) Worldwide, approximately 4,500 cardiac transplants are performed annually. Despite significant progress made in surgical techniques and post-operative care, the risks...Gene therapy technique could aid islet transplants for diabetes, says Pittsburgh study
...ombination of immunosuppressive drugs tacrolimus, sirolimus and daclizumab. After one day, and lasting three weeks, the blood glucose control was far superior in the HGF-treated rats than the controls. Also, the number of islets surviving in the liver in rats that had been transplanted with HGF-treated islets...Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
...nary stents coated with the immunosuppressive drug sirolimus are more likely to protect patients with coronary artery disease against futurenarrowing of coronary arteries (restenosis) than conventional metal stetns, conclude authors of a randomised trial in this week's issue of THE LANCET. The implantation of ...Organ transplant recipients face serious kidney-failure risk, study finds
...of three such drugs -- cyclosporine, tacrolimus or sirolimus -- it was impossible to tell exactly how much they may have contributed to an individual's kidney failure. The only statistically significant finding related to anti-rejection drugs was that the excess risk of developing chronic kidney failure was g...EliTE-Symphony study recruitment begins
...ined therapies such as cyclosporine, tacrolimus or sirolimus to non-toxic levels with no loss in efficacy, and with improved long-term outcomes. It is the study which the transplant world has been waiting for and its results are likely to have a great impact on immunosuppressive regimen selection in the future...Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
...or delivery of the drug via a stent. Cordis chose sirolimus for its cytostatic, rather than cytotoxic, properties, thereby inhibiting cell proliferation (cytostatic), rather than killing the cells (cytotoxic). Since its establishment in 1959, Cordis Corporation, along with its subsidiaries, has been a pionee...Stanford researcher dusts off old drug; uncovers new anti-rejection properties
...Cardiothoracic Surgery, elevated the drug - called sirolimus - from the brink of obscurity to its current role ...eat. Powerful immune-suppressing drugs - including sirolimus - keep the immune system under wraps and prevent this immediate rejection. Immune cells pass...